Please assess the completion status of the following clinical trial:

Trial Title: Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who met the following criteria were included:~* Males or females of any race, who were 12-75 years of age~* A body weight ≥ 20 kg and ≤ 150 kg and with a total serum IgE level ≥ 30 to ≤ 700 IU/ml~* A diagnosis of allergic asthma ≥ 1 year duration according to American Thoracic Society (ATS) criteria and at screening a history consistent with GINA (2204) step 3 or 4 clinical features~* A positive prick skin test (diameter of wheal \>= 3 mm) to at least one perennial allergen documented within the past 2 years or taken at visit 1~* Increase in FEV1 ≥12% over baseline value within 30 minutes of taking 2 to 4 puffs (2-4x100µg) salbutamol (albuterol) or nebulized salbutamol up to 5mg~* An FEV1 ≥ 40 and ≤ 80% of the predicted normal value for the patient at randomization~* Receiving moderate to high dose inhaled corticosteroid ≥ 800 µg BDP or equivalent and a regular inhaled long acting B-2 agonists for at least 3 months prior to screening and \> 1000 µg (BDP) and a LABA for at least 4 weeks during the run-in and at randomization~* Patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations while receiving high doses of ICS (≥ 800 µg BDP or equivalent) plus regular inhaled LABA~* Evidence of poor asthma control at screening (based on patient history) and for at least 4 weeks immediately prior to randomisation~Exclusion Criteria:~Patients who met the following criteria were excluded:~* Had received systemic corticosteroids for reasons other than asthma within 4 weeks of Visit 1~* A smoking history \>10 pack years~* An active lung disease other than allergic asthma~* Elevated serum IgE levels for reasons other than allergy~* Patients with significant underlying medical conditions

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- OAT + Omalizumab (Type: EXPERIMENTAL): During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
- Optimized Asthma Treatment (OAT) (Type: ACTIVE_COMPARATOR): During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).